Publicaciones en colaboración con investigadoras/es de University of Glasgow (19)

2023

  1. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. CT or Invasive Coronary Angiography in Stable Chest Pain

    New England Journal of Medicine, Vol. 386, Núm. 17, pp. 1591-1602

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

2021

  1. Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study

    European Radiology, Vol. 31, Núm. 3, pp. 1471-1481

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  2. Erratum: Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain (Health Qual Life Outcomes (2020) 18: 140 DOI: 10.1186/s12955-020-01312-4)

    Health and Quality of Life Outcomes

  3. Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain

    Health and Quality of Life Outcomes, Vol. 18, Núm. 1

  4. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

    The Lancet, Vol. 396, Núm. 10264, pp. 1745-1757

2019

  1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    The Lancet, Vol. 393, Núm. 10184, pp. 1937-1947

2017

  1. Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial

    European Radiology, Vol. 27, Núm. 7, pp. 2957-2968

  2. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1151-1210

  3. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016

    The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150

  4. Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015

    The Lancet, Vol. 390, Núm. 10091, pp. 231-266

2015

  1. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

    American Heart Journal, Vol. 169, Núm. 5, pp. 631-638.e7

  2. Serumuric acidandthe riskof cardiovascular and renal disease

    Journal of Hypertension, Vol. 33, Núm. 9, pp. 1729-1741

2014

  1. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

    BMJ Open, Vol. 4, Núm. 7

  2. Up-titration of allopurinol in patients with gout

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 1, pp. 25-30

2009

  1. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

    American Journal of Transplantation, Vol. 9, Núm. 5, pp. 1205-1213